Clinical Trial

Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-05
notable Primary completion pushed: 2026-06 -> 2026-10 2026-08-05
Trial Details
NCT Number NCT07291635
Lead Sponsor Aramis Biotechnologies Inc.
Conditions Influenza
Enrollment 728 participants
Start Date 2026-02-25
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-04